RLAY vs. NRBO
Compare and contrast key facts about Relay Therapeutics, Inc. (RLAY) and NeuroBo Pharmaceuticals, Inc. (NRBO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RLAY or NRBO.
Key characteristics
| RLAY | NRBO | |
|---|---|---|
| YTD Return | -28.61% | -11.82% |
| 1Y Return | -10.78% | -22.97% |
| 3Y Return (Ann) | -39.99% | -84.94% |
| Sharpe Ratio | -0.17 | -0.23 |
| Daily Std Dev | 85.96% | 101.85% |
| Max Drawdown | -90.41% | -100.00% |
| Current Drawdown | -87.23% | -100.00% |
Fundamentals
| RLAY | NRBO | |
|---|---|---|
| Market Cap | $1.28B | $27.67M |
| EPS | -$2.52 | -$4.99 |
| Total Revenue (TTM) | $35.21M | $4.00K |
| Gross Profit (TTM) | $29.71M | -$11.00K |
| EBITDA (TTM) | -$370.10M | -$26.51M |
Correlation
The correlation between RLAY and NRBO is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
RLAY vs. NRBO - Performance Comparison
In the year-to-date period, RLAY achieves a -28.61% return, which is significantly lower than NRBO's -11.82% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RLAY vs. NRBO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Relay Therapeutics, Inc. (RLAY) and NeuroBo Pharmaceuticals, Inc. (NRBO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RLAY vs. NRBO - Dividend Comparison
Neither RLAY nor NRBO has paid dividends to shareholders.
Drawdowns
RLAY vs. NRBO - Drawdown Comparison
The maximum RLAY drawdown since its inception was -90.41%, smaller than the maximum NRBO drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for RLAY and NRBO. For additional features, visit the drawdowns tool.
Volatility
RLAY vs. NRBO - Volatility Comparison
Relay Therapeutics, Inc. (RLAY) has a higher volatility of 48.72% compared to NeuroBo Pharmaceuticals, Inc. (NRBO) at 22.71%. This indicates that RLAY's price experiences larger fluctuations and is considered to be riskier than NRBO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RLAY vs. NRBO - Financials Comparison
This section allows you to compare key financial metrics between Relay Therapeutics, Inc. and NeuroBo Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities